The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives
Open accessAbstract
The present work aims to examine the worrying problem of antibiotic resistance and the emergence of multidrug-resistant bacterial strains, which have now become really common in hospitals and risk hindering the global control of infectious diseases. After a careful examination of these phenomena and multiple mechanisms that make certain bacteria resistant to specific antibiotics that were originally effective in the treatment of infections caused by the same pathogens, possible strategies to stem antibiotic resistance are analyzed. This paper, therefore, focuses on the most promising new chemical compounds in the current pipeline active against multidrug-resistant organisms that are innovative compared to traditional antibiotics: Firstly, the main antibacterial agents in clinical development (Phase III) from 2017 to 2020 are listed (with special attention on the treatment of infections caused by the pathogens Neisseria gonorrhoeae, including multidrug-resistant isolates, and Clostridium difficile), and then the paper moves on to the new agents of pharmacological interest that have been approved during the same period. They include tetracycline derivatives (eravacycline), fourth generation fluoroquinolones (delafloxacin), new combinations between one β-lactam and one β-lactamase inhibitor (meropenem and vaborbactam), siderophore cephalosporins (cefiderocol), new aminoglycosides (plazomicin), and agents in development for treating drug-resistant TB (pretomanid). It concludes with the advantages that can result from the use of these compounds, also mentioning other approaches, still poorly developed, for combating antibiotic resistance: Nanoparticles delivery systems for antibiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
(2015) · Microbe Magazine · doi:10.1128/microbe.10.354.1 · Cited by 2,266
Molecular Mechanisms of Antibacterial Multidrug Resistance
Alekshun, M. N., & Levy, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.03.004 · Cited by 1,647
Access to effective antimicrobials: a worldwide challenge
Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00474-2 · Cited by 1,465
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,215
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy149 · Cited by 1,160
The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance
Kowalska-Krochmal, B., & Dudek-Wicher, R. (2021) · Pathogens · doi:10.3390/pathogens10020165 · Cited by 1,039
Burden of Clostridium difficile on the Healthcare System
Dubberke, E. R., & Olsen, M. A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis335 · Cited by 557
Tetracycline antibiotics and resistance mechanisms
Nguyen, F., Starosta, A. L., Arenz, S., Sohmen, D., Dönhöfer, A., & Wilson, D. N. (2014) · Biological Chemistry · doi:10.1515/hsz-2013-0292 · Cited by 528
Deaths Attributable to Carbapenem-Resistant Enterobacteriaceae Infections
Falagas, M. E., Tansarli, G. S., Karageorgopoulos, D. E., & Vardakas, K. Z. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.121004 · Cited by 514
Shields, R. K., Nguyen, M. H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00883-17 · Cited by 495
Sartelli, M., Chichom-Mefire, A., Labricciosa, F. M., Hardcastle, T., Abu-Zidan, F. M., Adesunkanmi, A. K., Ansaloni, L., Bala, M., Balogh, Z. J., Beltrán, M. A., et al. (2017) · World Journal of Emergency Surgery · doi:10.1186/s13017-017-0141-6 · Cited by 494
Staphylococcus aureus: new evidence for intracellular persistence
Garzoni, C., & Kelley, W. L. (2009) · Trends in Microbiology · doi:10.1016/j.tim.2008.11.005 · Cited by 474
Zhanel, G. G., Golden, A. R., Zelenitsky, S., Wiebe, K., Lawrence, C. K., Adam, H. J., Idowu, T., Domalaon, R., Schweizer, F., Zhanel, M. A., et al. (2019) · Drugs · doi:10.1007/s40265-019-1055-2 · Cited by 446
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Sato, T., & Yamawaki, K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz826 · Cited by 379
Lomovskaya, O., Sun, D., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Griffith, D. C., & Dudley, M. N. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01443-17 · Cited by 353
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Eleraky, N. E., Allam, A., Hassan, S. B., & Omar, M. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020142 · Cited by 342
Trends in US Hospital Admissions for Skin and Soft Tissue Infections
Edelsberg, J., Taneja, C., Zervos, M., Haque, N., Moore, C., Reyes, K., Spalding, J., Jiang, J., & Oster, G. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.081228 · Cited by 326
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
Zhanel, G. G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Walkty, A., Gin, A. S., et al. (2016) · Drugs · doi:10.1007/s40265-016-0545-8 · Cited by 317
Zhai, J., Fong, C., Tran, N., & Drummond, C. J. (2019) · ACS Nano · doi:10.1021/acsnano.8b07961 · Cited by 280
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
Livermore, D. M., Warner, M., & Mushtaq, S. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt178 · Cited by 268
Antibiotics in late clinical development
Fernandes, P., & Martens, E. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.025 · Cited by 247
Bradford, P. A., Miller, A. A., O’Donnell, J. P., & Mueller, J. P. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00021 · Cited by 163
Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence
Pontali, E., Sotgiu, G., D’Ambrosio, L., Centis, R., & Migliori, G. B. (2016) · European Respiratory Journal · doi:10.1183/13993003.01891-2015 · Cited by 159
Clostridium difficilevirulence factors: Insights into an anaerobic spore-forming pathogen
Awad, M. M., Johanesen, P., Carter, G. P., Rose, E., & Lyras, D. (2014) · Gut Microbes · doi:10.4161/19490976.2014.969632 · Cited by 157
Karlowsky, J. A., Hackel, M., Tsuji, M., Yamano, Y., ECHOLS, R. M., & Sahm, D. F. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.007 · Cited by 149
Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection
Sheitoyan-Pesant, C., Chakra, C. N. A., Pépin, J., Marcil-Héguy, A., Nault, V., & Valiquette, L. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ958 · Cited by 144
Khalid, H. F., Tehseen, B., Sarwar, Y., Hussain, S. Z., Khan, W. S., Raza, Z. A., Bajwa, S. Z., Kanaras, A. G., Hussaın, I., & Rehman, A. (2018) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2018.10.049 · Cited by 137
Nitroimidazoles for the Treatment of TB: Past, Present and Future
Mukherjee, T., & Boshoff, H. I. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.90 · Cited by 130
Li, P., Chen, X., Shen, Y., Li, H., Zou, Y., Yuan, G., Hu, P., & Hu, H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.02.039 · Cited by 129
Eravacycline: A Review in Complicated Intra-Abdominal Infections
Scott, L. J. (2019) · Drugs · doi:10.1007/s40265-019-01067-3 · Cited by 120
Endimiani, A., Hujer, K. M., Hujer, A. M., Armstrong, E. S., Choudhary, Y., Aggen, J. B., & Bonomo, R. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00556-09 · Cited by 118
Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)
Baptista, R., Fazakerley, D. M., Beckmann, M., Baillie, L. W. J., & Mur, L. A. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-23110-1 · Cited by 107
Alm, R. A., Lahiri, S. D., Kutschke, A., Otterson, L. G., McLaughlin, R. E., Whiteaker, J. D., Lewis, L. A., Su, X., Huband, M. D., Gardner, H., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04456-14 · Cited by 99
Petty, L. A., Henig, O., Patel, T. S., Pogue, J. M., & Kaye, K. S. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s150447 · Cited by 98
Rodenak‐Kladniew, B., Montoto, S. S., Sbaraglini, M. L., Ianni, M., Ruiz, M. E., Talevi, A., Álvarez, V. A., Durán, N., Castro, G. R., & Islan, G. A. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118575 · Cited by 70
Tran, N. L., Hocquet, M., Eon, B., Sangwan, P., Ratcliffe, J., Hinton, T. M., White, J., Ozcelik, B., Reynolds, N. P., & Muir, B. W. (2018) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2018.02.048 · Cited by 68
Navalkele, B. D., & Chopra, T. (2018) · Biologics · doi:10.2147/btt.s127099 · Cited by 64
Siala, W., Kucharíková, S., Braem, A., Vleugels, J., Tulkens, P. M., Mingeot‐Leclercq, M., Dijck, P. V., & Françoise Van Bambeke, A. (2016) · Nature Communications · doi:10.1038/ncomms13286 · Cited by 62
Stability of cefiderocol against clinically significant broad-spectrum oxacillinases
Poirel, L., Kieffer, N., & Nordmann, P. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.11.005 · Cited by 58
Litwin, J. S., Benedict, M. S., Thorn, M. D., Lawrence, L. E., Cammarata, S., & Sun, E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04813-14 · Cited by 54
Snydman, D. R., McDermott, L. A., Jacobus, N. V., Kerstein, K. O., Grossman, T. H., & Sutcliffe, J. A. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02206-17 · Cited by 54
Zhang, Y., Kashikar, A., & Bush, K. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx261 · Cited by 52
Donà, D., Chiara, C. D., & Sharland, M. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.05.020 · Cited by 51
Morakul, B., Suksiriworapong, J., Chomnawang, M. T., et al. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.08.013 · Cited by 44
Safety of Delafloxacin: Focus on Adverse Events of Special Interest
Lodise, T. P., Corey, R. G., Hooper, D. C., & Cammarata, S. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy220 · Cited by 33
O’Donnell, J. P., Lawrence, K. W., Vishwanathan, K., Hosagrahara, V. P., & Mueller, J. P. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01808-18 · Cited by 32
Loading and releasing ciprofloxacin in photoactivatable liposomes
Ghosh, S., Qi, R., Carter, K. A., Zhang, G., Pfeifer, B. A., & Lovell, J. F. (2018) · Biochemical Engineering Journal · doi:10.1016/j.bej.2018.10.008 · Cited by 30
Ridinilazole: a novel antimicrobial for Clostridium difficile infection
Cho, J. C. (2018) · Annals of Gastroenterology · doi:10.20524/aog.2018.0336 · Cited by 27
Cited by
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023) · Pharmaceuticals · doi:10.3390/ph16111615 · Cited by 1,215
Abdallah, E. M., Alhatlani, B. Y., de Paula Menezes, R., & Martins, C. H. G. (2023) · Plants · doi:10.3390/plants12173077 · Cited by 327
Antibiotics and Bacterial Resistance—A Short Story of an Endless Arms Race
Baran, A., Kwiatkowska, A., & Potocki, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065777 · Cited by 300
Mining the UniProtKB /Swiss‐Prot database for antimicrobial peptides
Li, C., Sutherland, D., Salehi, A., Richter, A., Lin, D., Aninta, S. I., Ebrahimikondori, H., Yanai, A., Coombe, L., Warren, R. L., et al. (2025) · Protein Science · doi:10.1002/pro.70083 · Cited by 9
Metadata
- Authors
- Terreni, M., Taccani, M., & Pregnolato, M.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-05-02
- Volume
- 26
- Issue
- 9
- Pages
- 2671
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3159592417
- Cited by
- 596
- References
- 53
- FWCI
- 25.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.